Aerie Pharma (AERI) Reports Q2 Loss of $1.40/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Aerie Pharma (AERI) Reports Q2 Loss of $1.40/Share

Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

August 8, 2018 4:01 PM EDT

Conference Call and Webcast Today, August 8th, at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2018, along with a general business update.

Aerie Highlights

The Rhopressa® (netarsudil ophthalmic solution) 0.02% U.S. commercial launch commenced on April 30, 2018, and second quarter... More